Identification of genetic susceptibility to childhood: Cancer through analysis of genes in parallel

Cancer Genetics

Volumn 204, Issue 1, 2011, Pages 19-25

  Plon, Sharon E ^a   Wheeler, David A ^a   Strong, Louise C ^b   Tomlinson, Gail E ^c,d   Pirics, Michael ^a   Meng, Qingchang ^a   Cheung, Hannah C ^a   Begin, Phyllis R ^b   Muzny, Donna M ^a   Lewis, Lora ^a   Biegel, Jaclyn A ^e,f   Gibbs, Richard A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cancer susceptibility; Mutation analysis; Oncogenes; Rhabdoid tumors; Tumor suppressor genes

Indexed keywords

MESSENGER RNA;

ADULT; ARTICLE; CHILDHOOD CANCER; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DEVELOPMENTAL DISORDER; DNA REPAIR; FAMILY ASSESSMENT; FAMILY HISTORY; FANCD2 GENE; GENE DELETION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PEDIGREE ANALYSIS; PMS2 GENE; PRIORITY JOURNAL; SECOND CANCER; SMARCB1 GENE; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADOLESCENT; ALGORITHM; BIOLOGICAL MODEL; CHILD; DOMINANT GENE; GENE DOSAGE; GENETIC PREDISPOSITION; GENETICS; IMMUNOPRECIPITATION; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; ONCOGENE; RECESSIVE GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOID TUMOR;

ADOLESCENT; ADULT; ALGORITHMS; CHILD; DNA MUTATIONAL ANALYSIS; DNA REPAIR; GENE DOSAGE; GENES, DOMINANT; GENES, RECESSIVE; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOPRECIPITATION; MODELS, GENETIC; MUTATION; NEOPLASMS; ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOID TUMOR;

EID: 79955657639     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.11.001     Document Type: Article

References (25)

1. Plon SE, Nathanson K. Inherited susceptibility for pediatric cancer. Cancer J 2005;11:255-267.
2. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394: 203-206.
3. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79.
4. Eaton K, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011;56:7-15.
5. Hirsch B, Shimamura A, Moreau L, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004;103: 2554-2559.
6. Plon SE, Pirics ML, Nuchtern J, et al. Multiple tumors in a child with germ-line mutations in TP53 and PTEN. N Engl J Med 2008; 359:537-539.
7. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274.
8. Zhang J, Wheeler DA, Yakub I, et al. SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol 2005;1:-53.
9. Wong LJ, Dimmock D, Geraghty MT, et al. Utility of oligonucleotide array-based comparative genomic hybridization for detection of target gene deletions. Clin Chem 2008;54: 1141-1148.
10. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, et al. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003;100:2420-2425.
11. Gripp KW, Lin AE, Stabley DL, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 2006;140:1-7.
12. De Vos M, Hayward BE, Picton S, et al. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004;74: 954-964.
13. Picelli S, Zajac P, Zhou XL, et al. Common variants in human CRC genes as low-risk alleles. Eur J Cancer 2010;46: 1041-1048.
14. Liboutet M, Portela M, Delestaing G, et al. MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol 2006;126:1510-1517.
15. Janson K, Nedzi LA, David O, et al. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 2006;47:279-284.
16. Yuan ZQ, Gottlieb B, Beitel LK, et al. Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Hum Mutat 2002;19:108-113.
17. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21: 2397-2406.
18. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935.
19. Hulsebos TJ, Plomp AS, Wolterman RA, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007;80:805-810.
20. Boyd C, Smith MJ, Kluwe L, et al. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 2008;74:358-366.
21. Swensen JJ, Keyser J, Coffin CM, et al. Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1. J Med Genet 2009;46:68-72.
22. Kalb R, Neveling K, Hoehn H, et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet 2007;80:895-910.
23. Kuehn BM. 1000 Genomes Project promises closer look at variation in human genome. JAMA 2008;300:2715.
24. Alsbeih G, Story MD, Maor MH, et al. Chromosomal fragility syndrome and family history of radiosensitivity as indicators for radiotherapy dose modification. Radiother Oncol 2003;66: 341-344.
25. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992;326: 1309-1315.